222 related articles for article (PubMed ID: 19462433)
1. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
El Shabrawi-Caelen L; La Placa M; Vincenzi C; Haidn T; Muellegger R; Tosti A
Inflamm Bowel Dis; 2010 Feb; 16(2):182-3. PubMed ID: 19462433
[No Abstract] [Full Text] [Related]
2. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.
Osório F; Magro F; Lisboa C; Lopes S; Macedo G; Bettencourt H; Azevedo F; Magina S
Dermatology; 2012; 225(2):163-7. PubMed ID: 23052429
[TBL] [Abstract][Full Text] [Related]
3. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
[TBL] [Abstract][Full Text] [Related]
4. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
Salgueiro P; Lago P; Pedroto I
J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
[No Abstract] [Full Text] [Related]
6. First case report of adalimumab-induced psoriasis in Crohn's disease.
Harris MD; Richards R
Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
[No Abstract] [Full Text] [Related]
7. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
9. Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab.
Bordel-Gómez MT; Sánchez-Estella J; Martínez-González O; Cardeñoso-Alvarez ME
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):444-5. PubMed ID: 18624839
[No Abstract] [Full Text] [Related]
10. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
[TBL] [Abstract][Full Text] [Related]
12. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.
Barthel C; Biedermann L; Frei P; Vavricka SR; Kündig T; Fried M; Rogler G; Scharl M
Digestion; 2014; 89(3):209-15. PubMed ID: 24853251
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents.
Fiorino G; Danese S; Pariente B; Allez M
Autoimmun Rev; 2014 Jan; 13(1):15-9. PubMed ID: 23777821
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
16. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
Al-Mutairi A; Elkashlan M; Al-Fayed HM; Swayed M
Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571
[No Abstract] [Full Text] [Related]
17. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
Noda S; Mizuno K; Adachi M
J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
[TBL] [Abstract][Full Text] [Related]
18. Alopecia areata following adalimumab.
Kirshen C; Kanigsberg N
J Cutan Med Surg; 2009; 13(1):48-50. PubMed ID: 19298772
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease.
Toda-Brito H; Lopes L; Soares-Almeida L; Filipe P
Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632930
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
